Clinical Trials

188 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04534205 2026-04-15

AHEAD-MERIT

Phase 2/3 Recruiting

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06589804 2026-04-15

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

158 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06806852 2026-04-15

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

90 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07172256 2026-04-15

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07213934 2026-04-15

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07455032 2026-04-15

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

22 enrolled

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05232851 2026-04-14

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

20 enrolled 11 charts

Carcinoma, Oropharyngeal Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

BreastGastrointestinalHead & NeckThoracic

329 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT05172258 2026-04-13

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

52 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05913388 2026-04-13

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

92 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT06385080 2026-04-13

OrigAMI-4

Phase 1/2 Recruiting

287 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07276399 2026-04-13

OrigAMI-5

Phase 3 Recruiting

500 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02819752 2026-04-09

PEACH

Phase 1 Terminated

3 enrolled 12 charts

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

Phase 1 Completed

12 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

NCT04938609 2026-04-09

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05420948 2026-04-09

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Phase 2 Suspended

30 enrolled

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05077709 2026-04-08

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Phase 2 Completed

63 enrolled 18 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT06161545 2026-04-08

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

40 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03485209 2026-04-07

innovaTV 207

GastrointestinalHead & NeckThoracic

352 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04389632 2026-04-07

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT07513324 2026-04-07

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Phase 2 Not yet recruiting

116 enrolled

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05047094 2026-04-06

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Phase NA Recruiting

48 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms

NCT06790966 2026-04-06

VERSATILE-003

252 enrolled

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT07509099 2026-04-03

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

316 enrolled

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07264075 2026-04-02

ILLUMINE

780 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06236425 2026-04-01

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

7 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05980000 2026-03-31

Rambro2

37 enrolled

Phase 2/3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06295731 2026-03-31

HexAgon-HN

410 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07501650 2026-03-30

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

6 enrolled

Head and Neck Neoplasms, Recurrence

NCT03386357 2026-03-27

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Terminated

115 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT04199104 2026-03-27

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06525220 2026-03-27

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

500 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT07465276 2026-03-27

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04670679 2026-03-25

FLAGSHP-1

GastrointestinalHead & NeckSarcoma

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Chordoma, Neoplasm Metastasis, Neoplasms, Noonan Syndrome, Colorectal Neoplasms

NCT04858269 2026-03-24

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT07343596 2026-03-24

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

Phase NA Recruiting

20 enrolled

Mouth Neoplasms

NCT05059470 2026-03-23

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

Phase 2 Terminated

6 enrolled 8 charts

Thyroid Diseases

NCT06788990 2026-03-23

FORTIFI-HN01

Phase 2/3 Recruiting

650 enrolled

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT05537740 2026-03-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT07484139 2026-03-20

NEO COMBAT XL

Phase 2 Not yet recruiting

26 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

DermatologicGenitourinaryHead & NeckThoracic

36 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

DermatologicGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Phase 2 Completed

161 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06894771 2026-03-16

MK-4700-001

Phase 1 Completed

5 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03360890 2026-03-13

iPRIME

46 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts